Medicenna Therapeutics Corp has seen a decline in its stock performance this week, with no significant news driving the changes. Here's a closer look at the current state of MDNA.TO.
This week, Medicenna Therapeutics Corp (MDNA.TO) is experiencing a downward trend in its stock performance, marking a 4.11% decline over the past week. Despite the lack of major company news, recent headlines indicate ongoing developments related to public offerings that may influence investor sentiment.
Advertisement
Medicenna Therapeutics Corp
MDNA.TO
MDNA.TO
Medicenna Therapeutics Corp
WealthAwesomeAdvertisement
Market cap
$37.38M
52W high
$1.97
52W low
$0.34
1W change
+6.58%
Beta
1.89
Analyst Price Targets
Based on analyst covering MDNA
Wall Street analysts forecast MDNA stock price to rise 690.1% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.20
+690.1% Upside
Current Price
C$0.41
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDNA's historical volatility
30-Day Vol
40.5%
Annualized
90-Day Vol
68.5%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.34
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.38 | C$0.33 – C$0.44 |
| 60 trading days | C$0.36 | C$0.30 – C$0.44 |
| 90 trading days | C$0.34 | C$0.27 – C$0.43 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: While Medicenna's stock has dipped recently, analysts remain optimistic with a substantial target price indicating potential upside. Investors should consider the current technical indicators and market conditions when evaluating their positions.
Medicenna's stock is currently trading at C$0.35, down 4.11% this week.
The stock has a 52-week range of C$0.34 to C$1.97, indicating significant volatility over the past year.
Bull case
Analysts have set an average target price of C$3.20 for Medicenna, suggesting a potential upside of over 800%. This positive outlook is backed by the company's ongoing clinical trials and strategic initiatives that could drive future growth.
Bear case
The stock's performance has been inconsistent, with a year-to-date decline of 65%. This sharp drop means investors should proceed with caution. The company's negative profit margin and high beta signal volatility, which may be a concern for those looking to minimize risk.
Price Action Overview
Advertisement
Medicenna's stock closed at C$0.35, reflecting no change over the last day but a notable decline of 4.11% over the past week. The stock has struggled significantly this year, down 65% year-to-date.
Recent Company News
While there were no significant announcements from Medicenna this week, recent headlines include the finalization of terms for a public offering, where units are priced at C$0.50 each. This offering may provide the company with necessary capital for ongoing projects.
Technical Picture
Currently, Medicenna's stock is trading below both its 50-day moving average of C$0.43 and its 200-day moving average of C$0.84, indicating a bearish trend. The stock has a beta of 1.89, suggesting higher volatility compared to the broader market. The latest trading volume was 30,502 shares, well below the 20-day average volume of 76,616 shares, which may indicate lower investor interest.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
